Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Klara Kim, PharmD, will present her encore abstract, “Clinical Manifestations of Acute and Chronic Graft-vs-Host Disease With Posttransplant Cyclophosphamide in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation,” at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20.

Image Credit: © Justlight - stock.adobe.com

Originally shared at the 2025 American Pharmacists Association Annual Meeting and Exposition in Nashville, Tennessee, the abstract examines the incidence and severity of organ-specific graft-vs-host disease (GVHD) in patients who received posttransplant cyclophosphamide (PTCy) across various allogeneic transplant settings. Drawing on a retrospective analysis of more than 200 patients treated at City of Hope, the study aims to better characterize how GVHD manifests following PTCy-based prophylaxis, potentially guiding pharmacists in the identification and management of GVHD in clinical practice.

Abstract

Background

Established data on the efficacy of posttransplant cyclophosphamide (PTCy) for graft-vs-host disease (GVHD) prophylaxis in unrelated human leukocyte antigen (HLA)-matched and haploidentical-related allogeneic hematopoietic stem cell transplants (alloHCTs) has led to its increased use over conventional calcineurin inhibitor–based regimens. Although PTCy reduces the severity of acute and chronic GVHD, its clinical manifestations may vary across different transplant settings, creating opportunities to further describe in detail such manifestations. Through this retrospective study, our aim is to describe and distinguish the characteristics of GVHD, including the incidence and severity by organ involvement in patients who received PTCy for GVHD prophylaxis across various allogeneic transplant settings.

Materials and Methods

This is a single-center, retrospective analysis of approximately 200-plus adult patients who underwent alloHCT and received a PTCy-based regimen for GVHD prophylaxis following myeloablative or reduced-intensity conditioning between January 1, 2020, and December 31, 2023, at City of Hope National Medical Center in Duarte, California. PTCy recipients included those who received peripheral blood stem cells of haploidentical-related and mismatched unrelated donor transplants. Patients were excluded if they had chronic myeloid leukemia, used antithymocyte globulin, or had a second HCT using a PTCy-based GVHD prophylaxis regimen. The primary end point is to compare the incidence and severity of organ involvement in alloHCT patients who received PTCy.

Results

Results are pending and will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Conclusions

Conclusions are pending and will be presented at the OPC meeting in Austin, Texas, from June 19 to 20, 2025.

About the 2025 OPC Meeting

At this year’s OPC meeting, attendees will have the opportunity to showcase clinical research and practice management insights or explore the latest advancements in oncology pharmacy during the poster session and networking reception. These events foster innovation, collaboration, and professional growth within the oncology pharmacy community. Participants can present their work, exchange ideas, and connect with leaders in the field during these networking opportunities.

Prior to the start of OPC on June 19, participants are invited to attend the Hematology/Oncology Pharmacy Association (HOPA) BCOP Program in person on June 18. HOPA has selected 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. Additional information is available here.